Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Alignment Healthcare Surges Ahead with Strong Q3 Performance and Raised 2025 Outlook

Alignment Healthcare, a Medicare Advantage insurtech company, has reported impressive third-quarter results for 2025, showcasing robust growth and improved financial performance. The company's success story unfolds against the backdrop of a shifting Medicare Advantage landscape, highlighting its ability to adapt and thrive in a competitive market.

NoahAI News11/3/2025

Pfizer Sues Metsera and Novo Nordisk in Escalating Battle Over Obesity Drug Developer

In a dramatic turn of events in the pharmaceutical industry, Pfizer has initiated legal proceedings against Metsera and Novo Nordisk, intensifying a high-profile conflict over the acquisition of a promising obesity drug developer. The lawsuit, filed in Delaware Court of Chancery, marks a significant escalation in the battle between two pharmaceutical giants for control of Metsera's innovative weight loss medication portfolio.

NoahAI News11/2/2025

Edwards Lifesciences CFO to Step Down Amid Strong Q3 Performance and Strategic Shifts

Edwards Lifesciences, a leader in heart valve technologies, announced significant leadership changes and positive financial results in its recent third-quarter earnings report. The company's CFO, Scott Ullem, is set to exit his role by mid-2026, marking the second high-profile departure in recent months.

NoahAI News11/1/2025

Novo Nordisk's Bold Move Shakes Up Pharma Industry

In a surprising turn of events, Novo Nordisk, under the leadership of new CEO Maziar Mike Doustdar, has made an unsolicited bid of $8.5 billion for Metsera, a rising star in the obesity and metabolic medicine field. This move comes just weeks after Pfizer had seemingly secured a deal to acquire Metsera for nearly $5 billion, throwing the pharmaceutical industry into turmoil.

NoahAI News11/1/2025

AbbVie's Immunology Portfolio Drives Strong Q3 Performance, Surpassing Humira's Peak Sales

AbbVie reported robust third-quarter earnings, with its immunology portfolio spearheading growth and positioning the company for continued success. The pharmaceutical giant's two key drugs, Skyrizi and Rinvoq, have emerged as powerful successors to Humira, driving significant revenue and expanding their reach across multiple indications.

NoahAI News11/1/2025

Agilent Technologies Appoints Adam Elinoff as New CFO Amid Ongoing Transformation

Agilent Technologies, a leading analytical and clinical laboratory business, has announced the appointment of Adam Elinoff as its new Chief Financial Officer (CFO), effective November 17. This strategic move comes as part of the company's ongoing Ignite transformation program and fills a crucial vacancy left by the departure of former CFO Bob McMahon in July.

NoahAI News11/1/2025

Otsuka Pharmaceuticals Acquires Asia-Pacific Rights to 4DMT's Eye Disease Therapy for $85M Upfront

In a significant move within the ophthalmology drug development space, 4D Molecular Therapeutics has inked a deal with Japan's Otsuka Pharmaceuticals for the Asia-Pacific rights to its promising eye disease candidate, 4D-150. The agreement, announced on Thursday, involves an upfront payment of $85 million and could potentially exceed $400 million in total value.

NoahAI News11/1/2025

Eli Lilly Refines Pain Pipeline, Discontinues Mid-Stage Programs

Eli Lilly, a leading pharmaceutical company, has made significant changes to its pain medication pipeline, discontinuing two mid-stage assets while continuing to invest in novel pain therapies. These developments come as the company reports record-breaking financial results, driven by its blockbuster weight-loss franchise.

NoahAI News11/1/2025

Talkspace Reports Strong Q3 Growth, Expands AI Initiatives in Mental Health

Talkspace, a leading online therapy provider, has reported significant growth in its third-quarter earnings, driven primarily by its expanding payer business. The company is also making strides in artificial intelligence (AI) applications for mental health, positioning itself as a potential leader in the field amid growing scrutiny of generic AI chatbots.

NoahAI News11/1/2025

Thermo Fisher Scientific to Acquire Clario Holdings in $9B Deal, Boosting Clinical Trial Capabilities

Thermo Fisher Scientific, a leading life sciences company, has announced plans to acquire Clario Holdings, a clinical trial technology firm, in a deal valued at approximately $9 billion. The acquisition, set to close by mid-2026, aims to enhance Thermo Fisher's clinical research services and accelerate drug development processes.

NoahAI News11/1/2025

Lilly Cuts Pain Drug from Pipeline, Highlighting Challenges in Pain Research

Eli Lilly has quietly removed an experimental pain drug from its research pipeline, underscoring the ongoing challenges in developing effective treatments for chronic pain conditions. The decision, disclosed in the company's latest earnings report, reflects the broader difficulties faced by pharmaceutical companies in this complex therapeutic area.

NoahAI News11/1/2025

AAP Declines to Recommend Leucovorin for Autism, Citing Limited Evidence

The American Academy of Pediatrics (AAP) has issued interim guidance stating it does not recommend the routine use of leucovorin for children with autism spectrum disorder (ASD), citing insufficient evidence to support its widespread application. This announcement comes amidst recent developments in the pharmaceutical industry regarding potential treatments for autism and related conditions.

NoahAI News11/1/2025

1 2 3 4...67 »